Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Benepali

    - PMLiVE

    Eisai submits new drug application for subcutaneous Leqembi in Japan

    LEQEMBI is a treatment for early Alzheimer’s disease

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    - PMLiVE

    Novo Nordisk reports sales growth in 2025 as R&D pipeline advances

    Growth driven by increased sales in diabetes and obesity markets

    - PMLiVE

    Biogen expands portfolio in deal with Alcyone Therapeutics

    The agreement gives Biogen full rights to a potential therapy for patients with neurological disorders

    Biogen Idec building

    Biogen/Eisai’s Alzheimer’s drug Leqembi shows continued benefit over four years

    An estimated 13 million people in the US will be living with Alzheimer’s disease by 2050

    Biogen Idec building

    Biogen’s Qalsody granted MHRA approval to treat rare form of motor neurone disease

    Mutations in the SOD1 gene are responsible for approximately 2% of all cases of the disease

    Biogen Idec building

    Biogen to boost US manufacturing footprint with $2bn North Carolina investment

    The commitment is aimed at advancing the company's late-stage clinical pipeline

    - PMLiVE

    Uniphar Rebrands On Demand Business to Uniphar Global Sourcing, Strengthening Global Pharmaceutical Offering

    Dublin, Ireland 16th July 2025 – Leading global healthcare services provider, Uniphar, has launched Uniphar | Global Sourcing, a new identity for its On Demand business that strengthens its position...

    Uniphar

    EU flag

    EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy

    An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

    Biogen Idec building

    Biogen initiates phase 3 study of felzartamab in kidney disease patients

    Approximately 36,000 people in the US are affected by primary membranous nephropathy

    - PMLiVE

    Roche shares positive 96-week results for multiple sclerosis candidate fenebrutinib

    The immune-mediated disease affects more than 2.9 million people worldwide

    Biogen Idec building

    Biogen and City Therapeutics to develop RNAi therapies in deal worth over $1bn

    The partners will focus on a target that mediates key central nervous system diseases

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links